Outcome of patients with IDH1/2-mutated post myeloproliferative neoplasm AML in the era of IDH inhibitors

BLOOD ADVANCES

ELSEVIER

1. MD Anderson Cancer Center Support Grant from the National Cancer Institute, National Institutes of Health [P30 CA016672]
2. Lloyd Family/V Foundation Clinical Scholar Award